Combination of cataract surgery with intravitreal injection of dexamethasone intravitreal implant (Ozurdex) for uveitis-induced cataract

AIM: To evaluate the long-term results of patients with chronic uveitis-induced cataract by phacoemulsification with IOL implantation and intravitreal injection of dexamethasone (DEX) intravitreal implant (Ozurdex). METHODS: The study included 32 eyes of 26 patients treated with DEX implant due to c...

Full description

Bibliographic Details
Main Authors: Jin Deng, Wen-Tao Sun, Hua Ai, Li-Ping Wang
Format: Article
Language:English
Published: Press of International Journal of Ophthalmology (IJO PRESS) 2023-03-01
Series:International Journal of Ophthalmology
Subjects:
Online Access:http://ies.ijo.cn/en_publish/2023/3/20230305.pdf
_version_ 1827999878056247296
author Jin Deng
Wen-Tao Sun
Hua Ai
Li-Ping Wang
author_facet Jin Deng
Wen-Tao Sun
Hua Ai
Li-Ping Wang
author_sort Jin Deng
collection DOAJ
description AIM: To evaluate the long-term results of patients with chronic uveitis-induced cataract by phacoemulsification with IOL implantation and intravitreal injection of dexamethasone (DEX) intravitreal implant (Ozurdex). METHODS: The study included 32 eyes of 26 patients treated with DEX implant due to chronic uveitis-induced cataract and followed up for at least a year. Best-corrected visual acuity (BCVA), intraocular pressure (IOP), anterior chamber reaction, central macular thickness (CMT), intraoperative and postoperative complications and uveitis recurrence were analyzed retrospectively. RESULTS: A successful surgery was performed in all patients. The average follow-up period was 12mo. The female/male ratio was 13/13. Mean age was 45.65±3.83y (range 26 to 65y). Etiologically, rheumatic arthritis occurred in 6 patients (18.75%), ankylosing spondylitis in 4 (12.50%), HLA-B27 associated uveitis in 3 (9.38%), Vogt-Koyanagi-Harada-associated uveitis in 4 (12.50%) , Behcet's disease in 2 (6.25%), and 7 (21.88%) suffered from unknown diseases. All 32 eyes had varying degrees of improvement at 12mo after surgery, with 2 eyes showing BCVA of 0.1 or below (6.25%), 6 having 0.1-0.5 (18.75%), 18 of 0.5-1.0 (56.25%), and 6 of 1.0 or above (18.75%). No cases with increased IOP were observed. The values of mean CMT was increased at day 1, decreased at 1, 3mo after surgery and increased at 6, 12mo after surgery. No severe uveitis reactions, such as fibrinous exudates in the anterior chamber and exudative membrane formation on the anterior surface of the IOL, were observed after surgery. CONCLUSION: The present studies show that intravitreal injection of Ozudex during cataract operation can provide a new option for the clinical treatment of uveitis-induced cataract.
first_indexed 2024-04-10T06:06:20Z
format Article
id doaj.art-96dbf9adfb494429a363a1a428c8de6b
institution Directory Open Access Journal
issn 2222-3959
2227-4898
language English
last_indexed 2024-04-10T06:06:20Z
publishDate 2023-03-01
publisher Press of International Journal of Ophthalmology (IJO PRESS)
record_format Article
series International Journal of Ophthalmology
spelling doaj.art-96dbf9adfb494429a363a1a428c8de6b2023-03-03T03:26:29ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982023-03-0116336136610.18240/ijo.2023.03.0520230305Combination of cataract surgery with intravitreal injection of dexamethasone intravitreal implant (Ozurdex) for uveitis-induced cataractJin Deng0Wen-Tao Sun1Hua Ai2Li-Ping Wang3Wen-Tao Sun. Xi'an People's Hospital (Xi'an Fouth Hospital), Shaanxi Eye Hospital, Affiliated People's Hospital of Northwest University, Xi'an 710004, Shaanxi Province, China. swt926@126.comXi'an People's Hospital (Xi'an Fouth Hospital), Shaanxi Eye Hospital, Affiliated People's Hospital of Northwest University, Xi'an 710004, Shaanxi Province, ChinaXi'an People's Hospital (Xi'an Fouth Hospital), Shaanxi Eye Hospital, Affiliated People's Hospital of Northwest University, Xi'an 710004, Shaanxi Province, ChinaXi'an People's Hospital (Xi'an Fouth Hospital), Shaanxi Eye Hospital, Affiliated People's Hospital of Northwest University, Xi'an 710004, Shaanxi Province, ChinaAIM: To evaluate the long-term results of patients with chronic uveitis-induced cataract by phacoemulsification with IOL implantation and intravitreal injection of dexamethasone (DEX) intravitreal implant (Ozurdex). METHODS: The study included 32 eyes of 26 patients treated with DEX implant due to chronic uveitis-induced cataract and followed up for at least a year. Best-corrected visual acuity (BCVA), intraocular pressure (IOP), anterior chamber reaction, central macular thickness (CMT), intraoperative and postoperative complications and uveitis recurrence were analyzed retrospectively. RESULTS: A successful surgery was performed in all patients. The average follow-up period was 12mo. The female/male ratio was 13/13. Mean age was 45.65±3.83y (range 26 to 65y). Etiologically, rheumatic arthritis occurred in 6 patients (18.75%), ankylosing spondylitis in 4 (12.50%), HLA-B27 associated uveitis in 3 (9.38%), Vogt-Koyanagi-Harada-associated uveitis in 4 (12.50%) , Behcet's disease in 2 (6.25%), and 7 (21.88%) suffered from unknown diseases. All 32 eyes had varying degrees of improvement at 12mo after surgery, with 2 eyes showing BCVA of 0.1 or below (6.25%), 6 having 0.1-0.5 (18.75%), 18 of 0.5-1.0 (56.25%), and 6 of 1.0 or above (18.75%). No cases with increased IOP were observed. The values of mean CMT was increased at day 1, decreased at 1, 3mo after surgery and increased at 6, 12mo after surgery. No severe uveitis reactions, such as fibrinous exudates in the anterior chamber and exudative membrane formation on the anterior surface of the IOL, were observed after surgery. CONCLUSION: The present studies show that intravitreal injection of Ozudex during cataract operation can provide a new option for the clinical treatment of uveitis-induced cataract.http://ies.ijo.cn/en_publish/2023/3/20230305.pdfuveitis-induced cataractdexamethasone implantintravitreal injection
spellingShingle Jin Deng
Wen-Tao Sun
Hua Ai
Li-Ping Wang
Combination of cataract surgery with intravitreal injection of dexamethasone intravitreal implant (Ozurdex) for uveitis-induced cataract
International Journal of Ophthalmology
uveitis-induced cataract
dexamethasone implant
intravitreal injection
title Combination of cataract surgery with intravitreal injection of dexamethasone intravitreal implant (Ozurdex) for uveitis-induced cataract
title_full Combination of cataract surgery with intravitreal injection of dexamethasone intravitreal implant (Ozurdex) for uveitis-induced cataract
title_fullStr Combination of cataract surgery with intravitreal injection of dexamethasone intravitreal implant (Ozurdex) for uveitis-induced cataract
title_full_unstemmed Combination of cataract surgery with intravitreal injection of dexamethasone intravitreal implant (Ozurdex) for uveitis-induced cataract
title_short Combination of cataract surgery with intravitreal injection of dexamethasone intravitreal implant (Ozurdex) for uveitis-induced cataract
title_sort combination of cataract surgery with intravitreal injection of dexamethasone intravitreal implant ozurdex for uveitis induced cataract
topic uveitis-induced cataract
dexamethasone implant
intravitreal injection
url http://ies.ijo.cn/en_publish/2023/3/20230305.pdf
work_keys_str_mv AT jindeng combinationofcataractsurgerywithintravitrealinjectionofdexamethasoneintravitrealimplantozurdexforuveitisinducedcataract
AT wentaosun combinationofcataractsurgerywithintravitrealinjectionofdexamethasoneintravitrealimplantozurdexforuveitisinducedcataract
AT huaai combinationofcataractsurgerywithintravitrealinjectionofdexamethasoneintravitrealimplantozurdexforuveitisinducedcataract
AT lipingwang combinationofcataractsurgerywithintravitrealinjectionofdexamethasoneintravitrealimplantozurdexforuveitisinducedcataract